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Abstract.  Basic fibroblast growth factor (bFGF), a 
potent inducer of angiogenesis in vivo, stimulates the 
production of both urokinase- and tissue-type plas- 
minogen activators (PAs) in cultured bovine capillary 
endothelial cells. The observed increase in proteolytic 
activity induced by bFGF was effectively diminished 
by picogram amounts of transforming growth factor 
beta (TGFI3),  but could not be abolished by increasing 
the amount of TGFI~  However, the inhibition by TGFI3 
was greatly enhanced if the cells were pretreated with 
TGFI3 before addition of bFGE After prolonged incu- 
bation of cultures treated simultaneously with bFGF 
and TGF[~, the inhibitory effect of TGFI3 diminished 
and the stimulatory effect of the added bFGF domi- 
nated as assayed by PA levels. TGFI3 did not alter the 
receptor binding of labeled bFGF, nor did a 6-h pre- 
treatment with TGFI3 reduce the amount of bFGF 
bound.  The major difference between the effects of 
bFGF and TGFI3 was that while bFGF effectively 
enhanced PA activity expressed by the cells, TGFI3 
decreased the amounts of both cell-associated and 
secreted PA activity by decreasing enzyme production. 
Both bFGF and TGFI~ increased the secretion of the 
endothelial-type plasminogen activator inhibitor. 
T 
HE growth of new blood vessels in vivo occurs in nu- 
merous physiological and pathological  situations.  The 
most potent protein inducers  of neovascularization  in 
experimental  models are the heparin-binding  growth factors, 
a family of structurally  related  polypeptides (cf.,  15, 47). 
These proteins are divided into two closely related  groups, 
acidic fibroblast growth factors and basic fibroblast growth 
factors  (bFGFs),  ~ mainly on the basis of their elution pat- 
terns from immobilized heparin, their different pls, and their 
biological  characteristics.  Acidic  fibroblast growth  factor 
is a  single  chain  polypeptide with a  molecular weight of 
15,000-15,500 and a 55 % sequence homology with bFGF. It 
is 30-100-fold less potent as a mitogen  than bFGF, but the 
biologic activity of acidic fibroblast growth  factor  is  en- 
hanced by heparin (15, 47). bFGF has a molecular weight of 
18,500, a pI of greater than 9, and its biological activities are 
not enhanced by heparin,  bFGF has been isolated from nu- 
merous tissues, such as placenta (37), brain (12, 14), pituitary 
(4),  corpus luteum (13), and  several  cultured normal  and 
malignant  cell  lines  (22,  36,  42).  Both bFGF and acidic 
fibroblast growth factor induce plasminogen  activator  (PA) 
and collagenase production in bovine capillary endothelial 
(BCE) cells.  The secretion of PA and collagenases  by BCE 
1.  Abbreviations  used in  this paper:  BCE, bovine capillary  endothelial; 
bFGF, basic flbroblast growth factor;  PA, plasminogen  activator;  PAI 1, 
plasminogen activator inhibitor type  1; TGFI~, transforming growth factor 
beta;  tPA, tissue-type  plasminogen  activator;  uPA, urokinase-type  plas- 
minogen activator. 
cells  is  believed  to  be  important  for  migration  of  the 
capillary-forming  cells through  limiting  structures  such as 
basement membranes and intercellular  matrices (18). 
Two different types of serine proteinases are known to be 
effective PAs: the tissue-type PA (tPA) and the urokinase- 
type PA (uPA), which are products of two separate genes and 
differ both structurally and functionally (cf., 6, 43). The con- 
version of the  inactive  proenzyme plasminogen  to active 
plasmin by PAs is restricted and focused by specific inhibi- 
tors of the activation  reaction (cf., 45). These cell-secreted 
inhibitors  effectively control the proteolytic activity in the 
pericellular area by binding  extracellularly  activated  PAs. 
To further restrict and localize the proteolysis related  to 
plasminogen  activation,  proteinases are immobilized to the 
vicinity of  the cell. Active uPA bound to its membrane recep- 
tor (46, 49) is protected from the action of inhibitors  but 
retains  its  ability  to activate  plasmin,  which also may be 
immobilized to the membrane or pericellular area (19, 23, 
40, 44). 
Transforming growth factor beta (TGFI3) was initially iso- 
lated as part of the transformation-enhancing  activity derived 
from certain tumor cells (cf., 16, 21). TGFI3 expression is not 
limited to transformed cells. It is produced by a wide variety 
of normal tissues and is especially enriched in platelets  (1) 
and placenta  (10). The amount of "I'GF[$ in platelets exceeds 
that of  platelet-derived  growth factor (1). The effects of TGF[3 
on cultured cells vary depending  on culture conditions  and 
the cell types used. TGFI3 acts primarily as a growth inhibi- 
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chymal cells. The stimulation may be mediated through ac- 
tivation of the expression of other growth factors such as 
platelet-derived growth factor leading to an autocrine stimu- 
lation of the cells (29). One of the major metabolic effects 
of TGFI3 in cultured fibroblasts is induction of plasminogen 
activator inhibitor type I  (PAI  1) production (26,  27). 
In the present study we describe the opposite effects of 
bFGF and TGFI3 on the proteolytic balance of BCE cells. 
The inhibitory effect of  TGFI3 is mediated through a decrease 
in PA synthesis as well as increased secretion of an inhibitor 
of PA. Because of the numerous examples of platelet-endo- 
thelial interactions in hemostasis and wound healing, the ac- 
tivities of the platelet component TGFI3 and the endothelial 
cell or fibroblast product bFGF may be important in the reg- 
ulation of several endothelial functions. 
Materials and Methods 
Cell Cultures 
BCE cells were isolated from the bovine adrenal cortex according to pub- 
lished procedures (9, 18) and grown as described previously (37). When the 
cultures reached confluency, the serum concentration was reduced to 5 %. 
Cells were used between passages 8 and 12. Baby hamster kidney (BHK) 
cells were grown in DME containing 10% calf serum. 
Growth Factors 
bFGF was purified from term placentas (37, 42). The purified molecule has 
been sequenced and is homologous with bFGF purified from the bovine pi- 
tuitary (44b). Human platelet TGFI~ (1) was a kind girl from Drs. Assoian, 
Roberts, and Sporn (National Institutes of Health). Porcine platelet TGFI3 
was purchased from P,&D Systems (Minneapolis, MN). The two prepara- 
tions gave identical results. 
Antisera 
Rabbit antiserum against bovine PAI 1 purified from cultures of bovine aor- 
tic endothelial cells was a kind girl from D. Loskutoff (Scripps Clinic and 
Research Foundation, La Jolla, CA) (48).  Anti-uPA was prepared by im- 
munizing rabbits with purified human urokinase (60,000 IU/mg, 52 kD uro- 
kinase; Calbiochem-Behring Corp., La Jolla, CA) as described earlier (26). 
Anti-tPA was raised in rabbits against purified human melanoma tPA as de- 
scribed (35). 
Plasminogen Activator Assay 
BCE cells used for the experiments were grown on 24-well dishes (Falcon 
Labwares, Oxnard, CA). The PA activity in cell extracts was determined 
by the [125I]fibrin assay as described earlier (18). If not analyzed immedi- 
ately, the samples were kept frozen at -20°C. To measure secreted PA activ- 
ity, the conditioned medium (1 ml/well) was centrifuged at 2,000 g for 15 
min and kept frozen at -20°C until used. No difference in activity was ob- 
served between samples assayed immediately or frozen samples. 25 Ixl of 
the cell extract or 50 I~l of the conditioned medium were used in the assay, 
and the activity was presented in Ploug units (PU) using a urokinase stan- 
dard preparation (Leo Pharmaceuticals, Copenhagen, Denmark). 
Zymography 
SDS polyacrylamide gels with a 3% stacking gel and a 9% resolving gel 
were used for PA analysis (28).  For visualization of enzyme activities, 
fibrin-agar detector gels were placed in contact with the polyacrylamide 
gels (17). Samples for zymographic analysis were collected using 1 mM 
aprotinin (Trasylol, Bayer, Wuppertal, FRG) in both the growth medium and 
in the cell lysis buffer unless otherwise indicated. Catalytic amounts of  plas- 
min (fnal concentration 2  ng/ml, Sigma Chemical Co., St. Louis, MO) 
were included in the detector gel to activate the proactivator form of PA, 
unless otherwise indicated. 
Reverse zymography was carried out in a similar manner, except that, 
instead of plasmin, urokinase (0.05 PU/ml) was added to the detector gel 
to initiate fibrinolysis (8).  The agar gels were dried and stained with 0.1% 
Amido Black in 10%  acetic acid and 20% methanol. 
Iramunoprecipitation  of  Radiolabeled Proteins 
Confluent cultures of BCE cells growing on 60-ram petri dishes were in- 
cubated in serum-free medium for 8 h. The medium was removed and 4 ml 
of fresh serum-free medium containing 1 mM aprotinin was added with 
or without the growth factors. The cultures were incubated for 6 h, and 
L-[35S]methionine  (40 gCi/ml; New England Nuclear, Boston, MA) was 
added without changing the medium. After an additional incubation of 12 h, 
the conditioned medium was removed and centrifuged at 1,000 g for 15 min, 
followed by a  second centrifugation at  10,000 g  for 20 min.  Tween 80 
(0.05 %) was added to the samples. Cell extracts were prepared by dissolving 
the cells in 1 ml of 0.1 M Tris-HC1,  pH 7.5, containing 0.5% Triton X-100, 
0.1%  SDS, 0.05%  Tween 80, 0.15 M NaCI, and proteinase inhibitors (1.0 
mM  aprotinin,  1.0  mM  EDTA,  0.5  mM  N-ethylmaleimide,  2.0  mM 
phenylmethylsulfonyl fluoride  (PMSF),  final  concentrations), and  cen- 
trifuged at 10,000 g for 20 min. Before immunoprecipitation, the samples 
were diluted 1:5 with 0.1 M "IMs-HCI, pH 7.5, and preabsorbed with 20 Ixg 
of preimmune rabbit IgG and 50 Ixl of 50% (vol/vol) protein A-Sepharose 
(Sigma Chemical Co.) for 2 h at 4°C. After this treatment, 20 I~g of immune 
IgG was added together with 50 ul of  50% protein A-Sepharose  and the sam- 
ples were incubated as above. The immunoprecipitates were washed three 
times with cold PBS (0.15 M  NaC1 in 0.01 M  PO4 buffer,  pH 7.4)  and 
finally dissolved in reducing Laemmli sample buffer.  The immunoprecipi- 
tated proteins were analyzed by discontinuous 3-9 % PAGE, and the dried 
gels were subjected to autoradiography. 
Receptor Assays 
Confluent cultures of BCE cells on 60-mm dishes were incubated in serum- 
free medium overnight. The serum-free medium was changed, and the cells 
were further incubated for 6 h with or without 5 ng/ml TGF~ The cultures 
were than assayed for the binding of [125I]bFGF to high affinity sites as de- 
scribed for BHK cells (38). The cell-associated radioactivity was analyzed 
by the method of Scatchard (44a). 
To assay the ability of TGFI3 to compete for bFGF-binding to its receptor, 
confluent cultures of BHK cells on 24-well plates were used as described 
in reference 38. 
Results 
Stimulation of  PA Activity in BCE Cells by bFGF 
Purified placental bFGF increased the PA activity measured 
in BCE cell extracts in a dose- and time-dependent way both 
in the presence and in the absence of serum. In the absence 
of serum, half-maximal stimulation was obtained with  1-2 
ng/ml of bFGF during a 24-h incubation (Fig. 1 a, solid tri- 
angles), and an increase in the PA level was seen by 2-4 h 
after addition of the growth factor (data not shown). The PA 
activity secreted by the cells into serum-free medium cor- 
related  well  with  the  observed  stimulation  of the  cell- 
associated activity (data not shown).  This agrees with our 
earlier results showing that increases in cell-associated PA 
activity are representative of increases in secreted activity in 
BCE cells (18). 
Effect of TGFI3 on bFGF Stimulation of  PA 
Activity in BCE Cells 
Because of earlier experiments demonstrating that TGFI3 in- 
hibited P_A production in fibroblasts (26), we tested the effect 
of TGFI3 on PA  production by  BCE  cells.  In  serum-free 
medium, TGFI~ decreased the PA activity in cell extracts in 
a  time-  and dose-dependent manner  with  a  half-maximal 
concentration of 50 pg/ml (Fig. 1 b, open triangles). The in- 
hibitory effect on P_A levels in cell extracts was seen by 4  h 
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Figure 1. Modulation of cellular PA activity of BCE ceils by bFGF 
and TGFI~ Confluent cultures of BCE cells grown on 24-well plates 
were incubated in  1 ml of serum-free  medium containing bFGF 
or/and TGFI~ After a 24-h incubation,  medium was removed and 
the culture wells were washed with PBS. The cells were extracted 
and the PA activity of the cell extract was determined as described 
in Materials and Methods.  (A) The cells were stimulated with in- 
creasing amounts of bFGF (0-30 ng/ml) in the absence (A) or in 
the presence (zx) of a constant amount of TGFI3 (1 ng/ml). (B) In- 
creasing amounts of TFG[I (0-10 ng/ml) were added to the culture 
medium either in the absence (zx) or in the presence (A) of a con- 
stant amount of bFGF (3 ng/ml). 
after addition  of 1 ng/ml of TGFI3  to the culture medium 
(data not shown). The effect on secretion of PA activity was 
even more rapid with a decrease detectable by 2 h after addi- 
tion of the growth factor (data not shown). In the presence 
of 5 % calf serum, TGFI~ had little, if any, effect on the level 
of cell-associated PA activity (data not shown). The PA activ- 
ity in cell extracts from cultures  grown in 5 %  serum was 
comparable to that reached with ~1  ng/ml of TGFI3 under 
serum-free conditions. 
When increasing amounts of bFGF together with 1 ng/ml 
of TGFI3 were added to cultures of BCE cells in serum-free 
medium and the cultures were incubated for 24 h (Fig.  1 a, 
open triangles),  an increase in cellular PA activity was de- 
tected but at a lower level than that normally observed with 
bFGF alone (Fig. 1 a, solid triangles). When increasing con- 
centrations of TGFI3 were used to inhibit the stimulation by 
a constant amount of bFGF (3 ng/ml), a dose-dependent de- 
crease in PA levels was observed (Fig.  1 b, solid triangles). 
However, even at the highest concentrations used, TGFI~ was 
unable to abolish the stimulatory effect by bFGF on the PA 
activity in cell extracts, as can be seen by comparing the PA 
activities in cultures treated with both bFGF and TGFI3 (Fig. 
1 b, solid triangles) to PA activities in cultures treated with 
10 ng/ml of TGFI3 alone (Fig. 1 b, open triangles). However, 
the secreted PA activity in the culture medium became un- 
measurable with  increasing concentrations of TGFI3 (data 
not shown). 
If  bFGF was added 3-6 h before TGFI~, the TGFI3 appeared 
to have only a small effect on the stimulation of the cellular 
PA activity caused by bFGF (Fig.  2,  +6 and  +3).  On the 
contrary, if the cells were exposed to bFGF 3-6 h after addi- 
tion of 1 ng/ml of TGF~, a significant inhibition of the bFGF 
effect was seen (Fig. 2, -3 and -6). When added simultane- 
ously with bFGF, the same concentration of TGF[3 caused 
only a 50 % reduction in PA levels (Fig. 2,  O). Changes in 
the secreted activities followed the pattern observed with cel- 
lular  PA  activities  except  that  the  secreted  activities  de- 
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Figure 2. Effect of sequential addition of bFGF and TGF[3 on the 
cell-associated and secreted PA activities of BCE cells. The cells 
were grown on 24-well plates. After an 8-h incubation in serum-free 
medium, the cells were changed to fresh serum-free medium con- 
taining either 3 ng/ml bFGF or 1 ng/ml TGF~ At time points indi- 
cated, this preincubation medium was removed and replaced with 
a medium containing both growth factors. After an additional 18-h 
incubation,  the conditioned  medium was collected and the cells 
were extracted.  (Shaded bars) PA activity in cell extracts;  (open 
bars) PA activity in conditioned medium. 
creased more rapidly in the TGF~primed cultures and were 
below the level of detection in cultures exhibiting the maxi- 
mal TGFI3 effect (Fig. 2, open columns). 
When cultures treated simultaneously with both bFGF and 
TGFI~ were monitored for longer periods of time, the inhibi- 
tion caused by TGFI3 diminished.  After 2 d  of incubation, 
the cellular PA levels of cultures stimulated with increasing 
amounts ofbFGF and 1 ng/ml TGFI3 approached the cellular 
PA levels of parallel cultures stimulated with the same bFGF 
concentrations alone. Thus, the suppression of PA activity by 
TGF[~ seen at 24 h  is essentially lost after 48 h  (data not 
shown). 
Analysis of  PAs and PAls in BCE Cells after Treatment 
with bFGF  and TGF~ 
Zymography.  Analysis of the BCE cell extracts and condi- 
tioned medium by SDS-PAGE combined with detection of 
PA activities by a zymographic assay was used to identify the 
types of PAs secreted. Under serum-free conditions, cultured 
BCE cells contained and secreted both uPA and tPA (Fig. 3), 
although the amount of tPA was relatively small and was de- 
tectable only after prolonged incubation of the detector gel. 
The activities at 45,000 and 55,000 were shown to be due to 
uPA and tPA, respectively, by including inhibitory antibodies 
into zymography detector gels (data not shown). The results 
are in agreement with the previously described apparent mo- 
lecular weights of the bovine PAs (32, 35). Part of the PA ac- 
tivity found in conditioned medium, but not in cell extracts, 
appeared after prolonged incubation of the zymography test 
system as two high molecular weight bands of 90,000 and 
100,000 (data not shown). These high molecular weight PAs 
most likely represented enzymes bound to their common in- 
hibitor, PAI 1, since both of the high molecular weight ac- 
tivities  were  selectively  eliminated  from the  conditioned 
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cells in the presence of bFGF or TGFI3. The cells were incubated 
in serum-free medium in the presence of aprotinin (lanes 1 ) and ei- 
ther 3 ng/ml bFGF (lanes 2) or 1 ng/ml TGFI3 (lanes 3) for 24 h. 
(a) Cell extracts; (b) conditioned medium. 
medium by immunoprecipitation with antibodies against the 
bovine PAl 1. 
Exposure of the  cells to  bFGF  for 24  h  increased the 
amount of uPA activity in the cell extracts (Fig. 3 a, lane 2). 
In "l'GFI3-treated cells, only a small amount of PA activity at 
the 45,000-mol-wt region was detected (Fig. 3 a, lane 3). No 
complexed PA activity could be detected in any of the cell 
lysates. However, after prolonged storage of the cell lysates 
lacking aprotinin at 4°C,  the high molecular weight com- 
plexes appeared and were detected in zymography (data not 
shown). 
Analysis  of  the  conditioned  medium  by  zymography 
showed an increase in the 45-kD PA activity after stimulation 
of  the cells with bFGF (Fig. 3 b, lane 2). With longer incuba- 
tions of  the detector gel, the inhibitor-bound uPA activity be- 
came visible in the 90-kD region and was increased when 
compared to control cultures.  After treatment of the cells 
with TGFI~ (Fig. 3 b, lane 3), no tPA activity could be de- 
tected, and only a reduced amount of uPA activity could be 
seen in the 45-kD region. If plasmin was omitted from the 
detector gel in zymography (see Materials and Methods), no 
uPA activity was  visualized,  indicating that uPA was  in a 
proenzyme form.  Since high molecular weight complexes 
also were not detectable in the conditioned medium of  TGFI3- 
treated cells, even after prolonged zymography assays,  the 
expression of PA activity seemed to be totally inhibited by 
TGFI3. 
Reverse Zymography. Bovine aortic endothelial cells have 
been shown to synthesize large amounts of an inhibitor (PAl 
1) of PA (33, 48). To ascertain whether changes in the PA lev- 
els might reflect modulations of PAl 1 synthesis, the produc- 
tion of PAl  1 by BCE cells under different conditions was 
analyzed. Untreated BCE cells also synthesize and secrete 
a 47-kD PA inhibitor detectable by reverse zymography (Fig. 
4 a, lane 1). After addition of 3 ng/ml of bFGF to BCE cell 
cultures  in  the  presence of aprotinin,  an  increase  in  the 
amount of the secreted inhibitor activity could be seen by re- 
verse zymography (Fig. 4 a, lane 2). Addition of 1 ng/ml of 
TGFI3 resulted in a  marked increase in the amount of the 
secreted inhibitor (Fig. 4 a, lane 3). The inhibitor activity 
could be removed from the culture medium of TGFI3-treated 
cells by immunoprecipitation with antibodies against PAI  1 
(Fig. 4 a, lane 4). The levels of inhibitor activity in the cell 
Figure 4.  Reverse zymography demonstrating the effect of bFGF 
and TGF~ on the endothelial type PA inhibitor (PAl 1) activity in 
BCE cell cultures. Serum-free conditioned medium from cell cul- 
tures  was  analyzed  by  reverse  zymography  as  described  in 
Materials and Methods. (A) Samples collected in the presence of 
aprotinin. (Lane 1) control cells; (lane 2) 3 ng/ml bFGF present 
for 24 h; (lane 3) l ng/ml  TGFI~  present for 24 h; (lane 4) 1 ng/ml 
of TGFI3 present for 24 h followed by absorbing the conditioned 
medium with antibodies to PAId. (B) Samples collected in the ab- 
sence ofaprotinin. (Lane 1) TGFI~  (1 ng/ml) added 6 h before bFGF 
(3 ng/ml); (lane 2) TGFI3 (1  ng/ml) and bFGF (3 ng/ml) added 
simultaneously; (lane 3) bFGF (3 gg/ml) added 6 h before TGFI3 
(1 ng/ml); (lane 4) TGFI3 (1 ng/ml). 
extracts were also increased after the growth factor treatment 
(data not shown). 
When both bFGF and TGFI3 were simultaneously or se- 
quentially added to the cultures in the presence of aprotinin, 
the reverse zymography showed an increase in the amounts 
of the detectable inhibitor (data not shown). However, if the 
incubation was carried out in the absence of aprotinin, the 
amount of inhibitor activity was high when TGFfl was added 
to the cells 6 h before bFGF (Fig. 4 b, lane 1 ) or when both 
growth factors were added simultaneously (Fig. 4 b, lane 2). 
However, if bFGF was added alone (not shown), or 6 h be- 
fore TGFI$ (Fig. 4 b, lane 3), the amount of the inhibitor ac- 
tivity appeared to be less than when TGFI3 alone was added 
to the cultures (Fig. 4 b, lane 4). The cultures pretreated with 
bFGF showed elevated PA activity (Fig. ~2, +6). The appar- 
ent decrease in the inhibitor activity may be explained by in- 
creased activation of secreted pro-uPA  in  the  absence of 
aprotinin, which leads to consumption of PAI-1 activity in 
the conditioned medium. 
lmmunoprecipitation.  Immunoprecipitation  from  the 
conditioned medium with antibodies against  uPA  (Fig.  5) 
and subsequent quantitation of the metabolically labeled en- 
z)/me from autoradiograms by scanning densitometry dem- 
onstrated a 2.1-fold increase in the secreted uPA after treat- 
ment with 3  ng/ml bFGF (Fig.  5,  lane 2)  and an 8.3-fold 
decrease in the secreted enzyme after treatment with 1 ng/ml 
TGFI3 (Fig. 5, lane 3) for 24 h, when compared to uPA secre- 
tion from parallel cultures of untreated BCE cells (Fig.  5, 
lane 1). 
Immunoprecipitation with antibodies against PAl  1 dem- 
onstrated the synthesis of the inhibitor by BCE cells. After 
treatment of the cells with 3 ng/ml of bFGF in the presence 
of aprotinin for 18 h, the amount of PAl 1 precipitated from 
both conditioned medium and cell extracts of these cultures 
had increased (Fig. 5, lanes 5 and 8) when compared to un- 
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collected in the absence of aprotinin, a larger proportion of 
the labeled protein was detectable as a 90-kD complex (not 
shown). After treatment with 1 ng/ml of TGFI3 for 24 h, an 
even more remarkable increase in the production of PAl  1 
was seen (Fig. 5, lanes 6 and 9). When quantitated by scan- 
ning densitometry from the autoradiograms, the increase of 
PAl 1 secreted to the conditioned medium after treatment of 
the cultures with bFGF was 2.2-fold and after treatment with 
TGFI3 5.8-fold. 
Receptor Assays 
The decreased response of BCE cells to bFGF caused by 
TGF[3  might  result  from TGF[i  directly  competing  with 
bFGF for binding to its receptor or to a reduction in the num- 
ber of bFGF receptors induced by TGF[I. Therefore, we in- 
vestigated  the  ability  of  TGF[3  to  block  the  binding  of 
[125I]bFGF to its receptor. BHK cells were used for this ex- 
periment since they are rich in bFGF receptors and can eas- 
ily be used in the receptor-binding experiments. When BHK 
cells were incubated at 4°C with  1 ng/ml of [~25I]bFGF in 
the presence of various concentrations of TGF~ the binding 
of [m25I]bFGF to high affinity sites on the cells was not af- 
fected by concentrations of TGF[3 up to 1(30  ng/ml (Table I). 
In  a  parallel  experiment,  10  ng/ml  of  unlabeled  bFGF 
blocked 75 % of the binding of [125I]bFGF to high affinity 
sites.  These results demonstrate that TGF[I cannot directly 
prevent the binding of bFGF to its receptor. 
TGF[3 might also exert its effect by causing a decrease in 
the number ofbFGF receptors. To investigate this, BCE cells 
were incubated in serum-free medium overnight, the medi- 
um was changed and the cells were further incubated with 
or without 5 ng/ml TGF[~ for 6 h. The cells were washed and 
assayed for the presence of bFGF receptors. No decrease in 
the binding of [~25I]bFGF to BCE cells was detected after 
this pretreatment with TGF[~ indicating no decrease in the 
number of bFGF receptors under these conditions (data not 
shown). 
Discussion 
In  the  present  study  we  describe the  opposing  effects of 
bFGF and TGFfl on the PA activity of cultured BCE cells. 
bFGF caused a pronounced increase in PA production, while 
TGFI3 caused a  decrease in enzyme synthesis.  The simul- 
taneous administration of bFGF and TGFI3 to BCE cell cul- 
tures resulted in the inhibition of the bFGF-mediated stimu- 
lation  of PA  activity.  The  inhibitory effect could  not  be 
abolished by increasing the amounts of bFGF, nor could the 
stimulation  by  bFGF  be  completely  suppressed  by  high 
amounts of TGFI3. These findings suggest that the effects of 
these  growth  factors are  mediated by different receptors. 
Consistent with this idea is the result that TGF~ did not com- 
pete with the receptor binding of bFGF in BHK cells. This 
is in agreement with the results of Frater-Schroder et al. (11) 
and Baird and Durkin (2) who described the opposing effects 
of these growth factors on endothelial cell proliferation. 
It appears that in the presence of both growth factors, the 
cellular response is dependent upon the order of addition of 
the factors, the time of addition of the second growth factor, 
and,  to a  lesser extent, the relative concentrations of the 
growth factors. It is interesting to note that by first inhibiting 
Figure 5.  Immunoprecipitation of metabolically labeled uPA and 
PAl 1 from cultures of bFGF- and TGF~-treated BCE cells. The 
cells were first incubated in serum-free medium containing 1 mM 
aprotinin and 3 ng/ml bFGF or 1 ng/ml TGFI~ for 6 h. Without 
changing the medium, 50 l~Ci/ml [35S]methionine  was then added, 
and the cultures were incubated for 12 h. The proteins were ana- 
lyzed by SDS-PAGE with a  12% (lanes 1-3) or 9% (lanes 4-12) 
separation gel. Lanes 1-3 demonstrate the precipitated uPA from 
conditioned medium and lanes 4-9 the precipitated PAI 1 from con- 
ditioned medium (lanes 4-6) and cell extracts (lanes 7-9). Control 
precipitations  from the  cell  extracts with  nonimmune  IgG  are 
shown in lanes 10-12. (Lanes 1, 4,  7, and 10) Control cultures; 
(lanes 2, 5, 8, and 11) cultures treated with bFGF (3 ng/ml); (lanes 
3, 6, 9, and 12) cultures treated with TGFI3 (1 ng/ml). 
the PA activity by picogram amounts of TGFI3, then remov- 
ing the TGFI3 and adding nanograms of bFGE it is possible 
to regulate the PA-dependent proteolytic activity of the BCE 
cells several hundredfold. 
The  description  of the  precise  molecular changes  that 
yield the variations in total PA activity demonstrated in our 
assays is complex. The cells produce both tPA and uPA, and 
the uPA is produced as an inactive proenzyme. The final 
product of the activation cascade, plasmin, is capable of con- 
Table I. Binding of l7251]bFGF to High Affinity Receptors 
in the Presence of TGF~ or Unlabeled bFGF 
[rz~I]bFGF bound to high 
affinity sites (fmol/IO  s cells) 
Concentration  of 
competing ligand  TGFI3  bFGF 
ng/ml 
0  7.18  6.81 
1  8.40  5.56 
10  7.59  2.16 
100  8.30  0.88 
BHK cells on 24-well plates (105cells/plate) were incubated for 2 h at 4"C in 
DME containing 0.15%  gelatin, 25 mM Hepes, pH 7.5,  I ng/ml [~251]bFGF, 
and the indicated concentration of TGFI3 or unlabeled bFGF. At the end of the 
incubation,  the cells were washed three  times with PBS and once with 2 M 
NaCI in 20 mM Hepes, pH 7.5, to remove  [J2SI]bFGF  bound to low affinity 
sites.  The  [125I]bFGF bound  to high  affinity sites  was then  extracted  with 
0.5%  Triton  X-100 in 0.1  M sodium phosphate,  pH 8.1. 
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large amounts of an inhibitor of both uPA and tPA, the en- 
dothelial type PA inhibitor or PAI 1. This inhibitor, as iso- 
lated from conditioned medium in tissue culture, appears to 
be primarily in a latent form (20, 30), and the mode of its 
possible activation or reactivation is not understood at this 
time. Denaturants like SDS and guanidine are effective in 
reactivating the latent form of PAI 1, and this apparently also 
takes place during the reverse zymography. In the BCE cell 
culture system, some active inhibitor is present, as evidenced 
by the formation of PA inhibitor complexes detected after 
electrophoresis. However, relatively small amounts of com- 
plexes appear to be formed, since the inhibitor-enzyme com- 
plexes observed by zymography  or immunoprecipitation rep- 
resent only a small fraction of the total amount of either the 
detectable PA activity or the radiolabeled inhibitor. This may 
be partly due to the instability of the complex between uPA 
and PAl 1 (39). 
The stimulatory effect of bFGF on the PA levels of BCE 
cells was due to the increased production and secretion of 
PAs, as shown earlier (37, 42). This was seen by zymography 
as an increase of the plasminogen-dependent lysis areas cor- 
responding to uPA and tPA,  in the [t25I]fibrin degradation 
assay as an increase in total activity in both conditioned 
medium and cell extracts, and after immunoprecipitation as 
an increase in metabolically labeled uPA. If the plasmin in- 
hibitor  aprotinin  was  included during  sample  collection, 
most of the uPA seen after stimulation by bFGF appeared as 
a 45-kD species whose activity was greatly enhanced by the 
presence  of plasmin  in  the  zymography detector  gel.  If 
aprotinin was omitted, increasing amounts of uPA activity 
appeared in the 90-kD region indicating the formation of in- 
hibitor-enzyme complexes under these conditions.  These 
results indicate that most of the uPA secreted after stimula- 
tion with bFGF is in the proactivator form and becomes acti- 
vated by plasmin present in the culture as shown earlier (cf., 
6). A small increase in the rate of pro-uPA activation to uPA 
and subsequent complex formation with the inhibitor occurs 
during stimulation with bFGF in spite of the presence of 
aprotinin.  However,  it is difficult to interpret the possible 
functional relevance of  this finding on the basis of the present 
results. This finding may indicate that part of the pro-uPA- 
uPA conversion takes place at sites not reached by aprotinin 
or that aprotinin is unable to block all of the plasmin activity 
in the cultures. 
A remarkable increase in the amount of the secreted PAI 
1 occurred, when the BCE cells were treated with pg/ml con- 
centrations of  TGF~ Simultaneously, the amounts of  uncom- 
plexed and complexed PAs seen by zymography rapidly de- 
creased, and the amount of secreted uPA antigenicity fell. 
Thus,  the differences in the detectable PA activities after 
bFGF and TGFI3 treatments appear to be due to alterations 
in the rate of enzyme synthesis and secretion by the cells and 
possibly in proenzyme activation. Both growth factors in- 
crease the secretion of PAI 1. Addition of 5 % serum to BCE 
cells caused a decrease in PA activity equal to the addition 
of 1 ng/ml of TGFI3. A suppression of PA production after 
addition of fresh serum to cultures of aortic endothelial cells 
has also been shown by Levin and Loskutoff (31). Since se- 
rum contains biologically active TBFI3 (5,  34),  the serum 
effect on PA activity may be partly due to the action of TGFIS. 
The highest concentration of TGFI3 is found in platelets, 
and TGFI5 is released during thrombus formation (1). The 
main function of a thrombus is to achieve hemostasis, and 
several of the initial steps in clot formation are directed to- 
wards the prevention of premature lysis of the formed plug. 
Thus, the suppression of PA production by the endothelium 
by the release of TGFI3 should result in a decrease in the 
fibrinolytic activity and promote clot maintenance. In addi- 
tion, the rapid stimulation of high levels of PAI 1 secretion 
from the  surrounding capillary  cells  by platelet-released 
TGFI3 as well as PAI 1 release from the platelets themselves 
(7, 25) may further suppress fibrinolysis by inhibiting both 
uPA and tPA (24).  PAl 1 is transiently deposited in the peri- 
cellular area of fibroblasts or fibrosarcoma cells (26, 41). This 
immobilization, which also takes place in cultures of BCE 
cells particularly after treatment with TGFI3 (Saksela, O. 
unpublished  observations),  may  further  add to  the  local 
antifibrinolytic  activity  of  PAI  1  secreted  by  the  en- 
dothelium. The reversibility of the TGFI3 effect on BCE cells 
may be important in relation to the subsequent onset of clot 
lysis or angiogenesis leading to thrombus reorganization and 
wound healing; effects possibly mediated by bFGF released 
by resident cells (36), or by macrophages invading the area 
(3). The bFGF-mediated process of migration and prolifera- 
tion of endothelial cells, as well as the degradation of the 
basement membrane and matrix macromolecules, would re- 
quire that the TGFI3 effect be transient so as not to suppress 
these activities. 
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